Dapirolizumab (anti-CD40L) - Primary antibody, specific to CD40LG, Human IgG1

Cat. No.: Ab191960

GRADE & PURITY Animal Free, Carrier Free, Recombinant, Validated, ExactAb™, Low Endotoxin, Azide Free, ≥95%(SDS-PAGE&SEC-HPLC), See COA

Application

Animal Model, ELISA, Flow Cytometry, Functional Assay

Host species

Human

Reactive species

Cynomolgus monkey, Human

Isotype

Human IgG1

Conjugation

Unconjugated

Overview

Dapirolizumab (anti-CD40L) is a monoclonal antibodi against CD40 ligand. Dapirolizumab (anti-CD40L) targets CD40L, blocks its interaction with CD40 receptors, and inhibits adaptive immune activation. Dapirolizumab (anti-CD40L) attenuates systemic lupus erythematosus.

Specifications

Product Name

Dapirolizumab (anti-CD40L) - Primary antibody, specific to CD40LG, Human IgG1

Synonyms

CD154 antibody | CD40 antigen ligand antibody | CD40L antibody | CD40LG antibody | Gp39 antibody | HIGM1 antibody | Hyper IgM syndrome antibody | IGM antibody | IMD3 antibody | Ly62 antibody | T B cell activating molecule antibody | TBAM antibody | TNF re

Specifications & Purity

Carrier Free, Recombinant, ExactAb™, Low Endotoxin, Azide Free, Validated, Animal Free, ≥95%(SDS-PAGE&SEC-HPLC), See COA

Biochemical and Physiological Mechanisms

The protein encoded by this gene is expressed on the surface of T cells. It regulates B cell function by engaging CD40 on the B cell surface. A defect in this gene results in an inability to undergo immunoglobulin class switch and is associated with hyper

Host species

Human

Specificity

CD40LG

Conjugation

Unconjugated

Grade

Animal Free, Azide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated

Isotype

Human IgG1

Light Chain Type

kappa

SDS-PAGE

145 kDa

Purification Method

Protein A purified

Concentration

See COA

Storage and Shipping

Storage

Store at -80°C,Avoid repeated freezing and thawing

Shipped In

Dry ice packs + Cold packs

Stability And Storage

Store at -80℃ for 24 months. Upon receipt, it is recommended to aliquot. Avoid freeze/thaw cycle.

Images

Flow Cytometry: Dapirolizumab (anti-CD40L) (Ab191960)

Dapirolizumab (anti-CD40L) (Ab191960) - Flow Cytometry
Flow Cytometry analysis of unstimulated (left) or 500 ng/mL Ionomycin (I139530) and 10 ng/mL PMA (P408905) co-stimulated (right) Jurkat cells labelling CD40L (red) with Dapirolizumab (anti-CD40L) (Ab191960) at 0.1 μg/mL for 1 hour at 4°C. Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.

ELISA: Dapirolizumab (anti-CD40L) (Ab191960)

Dapirolizumab (anti-CD40L) (Ab191960) - ELISA
Immobilized Recombinant Human CD40 Ligand/TNFSF5 protein (rp189423) at 1.0 μg/mL can bind Dapirolizumab (anti-CD40L) (Ab191960) with the EC₅₀ of 28.88 ng/mL.

SEC: Dapirolizumab (anti-CD40L) (Ab191960)

Dapirolizumab (anti-CD40L) (Ab191960) - SEC
The purity of Dapirolizumab (anti-CD40L) (Ab191960) is more than 95% verified by HPLC.

Associated Targets(Human)

CD40LG Tbio CD40 ligand (0 Activities)

Discover Target: CD40LG

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

Mechanisms of Action